Japan Post-Marketing Surveillance - Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
Status: Recruiting
Location: See all (47) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The objective of this study is to investigate the safety and effectiveness in routine clinical practice and actual clinical setting for all patients with rheumatoid arthritis (RA) treated with peficitinib.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• All patients with rheumatoid arthritis (RA) treated with peficitinib for the first time.
Locations
Other Locations
Japan
Site JP00023
RECRUITING
Aichi
Site JP00005
RECRUITING
Akita
Site JP00002
RECRUITING
Aomori
Site JP00012
RECRUITING
Chiba
Site JP00038
RECRUITING
Ehime
Site JP00018
RECRUITING
Fukui
Site JP00040
RECRUITING
Fukuoka
Site JP00007
RECRUITING
Fukushima
Site JP00021
RECRUITING
Gifu
Site JP00010
RECRUITING
Gunma
Site JP00034
RECRUITING
Hiroshima
Site JP00001
RECRUITING
Hokkaido
Site JP00028
RECRUITING
Hyōgo
Site JP00008
RECRUITING
Ibaraki
Site JP00017
RECRUITING
Ishikawa
Site JP00037
RECRUITING
Kagawa
Site JP00046
RECRUITING
Kagoshima
Site JP00014
RECRUITING
Kanagawa
Site JP00039
RECRUITING
Kochi
Site JP00043
RECRUITING
Kumamoto
Site JP00026
RECRUITING
Kyoto
Site JP00024
RECRUITING
Mie
Site JP00004
RECRUITING
Miyagi
Site JP00045
RECRUITING
Miyazaki
Site JP00020
RECRUITING
Nagano
Site JP00042
RECRUITING
Nagasaki
Site JP00029
RECRUITING
Nara
Site JP00015
RECRUITING
Niigata
Site JP00003
RECRUITING
Numakunai
Site JP00044
RECRUITING
Ōita
Site JP00033
RECRUITING
Okayama
Site JP00047
RECRUITING
Okinawa
Site JP00027
RECRUITING
Osaka
Site JP00041
RECRUITING
Saga
Site JP00011
RECRUITING
Saitama
Site JP00025
RECRUITING
Shiga
Site JP00032
RECRUITING
Shimane
Site JP00022
RECRUITING
Shizuoka
Site JP00009
RECRUITING
Tochigi
Site JP00036
RECRUITING
Tokushima
Site JP00013
RECRUITING
Tokyo
Site JP00031
RECRUITING
Tottori
Site JP00016
RECRUITING
Toyama
Site JP00030
RECRUITING
Wakayama
Site JP00006
RECRUITING
Yamagata
Site JP00035
RECRUITING
Yamaguchi
Site JP00019
RECRUITING
Yamanashi
Contact Information
Primary
Astellas Pharma Inc.
astellas.registration@astellas.com
Time Frame
Start Date: 2019-09-02
Estimated Completion Date: 2026-05-31
Participants
Target number of participants: 3000
Treatments
Peficitinib
Participants will receive peficitinib once daily after meal.
Related Therapeutic Areas
Sponsors
Leads: Astellas Pharma Inc